What is peptide therapy? What clinics offer and how to check one

“Peptide therapy” is a clinic term, not a medical one. It means a prescriber, often at a wellness clinic, med spa or telehealth service, prescribing peptides for goals such as weight loss, aging, injury recovery, sleep or sexual function, usually as injections under the skin. Under that one label sit very different things: FDA-approved drugs, compounded drugs, and unapproved peptides. If the word itself is new, our peptide basics start with what peptides are, and the FDA status tracker gives the status of each one.

NAD+, often sold in the same programs, is not a peptide. It is a coenzyme in FDA’s 503A category 1, which means pharmacies may compound it under an interim policy while FDA evaluates it.

How does peptide therapy work?

There is no single mechanism, because each peptide is a different drug with its own target. GLP-1 drugs act on appetite and blood sugar. Tesamorelin signals the pituitary to release growth hormone. Bremelanotide acts on receptors in the brain. The therapy part is the service around the drug: an intake form or visit, a prescription, a shipment, and usually a monthly fee. Most products are injected under the skin at home, and some come as nasal sprays or creams. The injection sites guide covers the technique, and the labels differ on where a drug can go.

What is peptide therapy used for?

Clinics market it for weight loss, muscle, recovery, sleep, skin, hair, sexual function and aging. Only some of those goals have an approved peptide behind them. Weight loss does. Muscle, skin, sleep and injury healing do not, and the goals overview sets out what the human evidence shows for each. A clinic can offer an approved drug for its labeled use, an approved drug off-label, or an unapproved product, and those are very different propositions wearing the same name.

What is FDA-approved and what is not

Only the drugs, never the program, carry FDA approval. Each approved peptide is approved for something specific, and the label says what:

• Semaglutide and tirzepatide are approved for type 2 diabetes and chronic weight management, with more uses added over time. These are the best-studied drugs in any peptide program.
• Tesamorelin (Egrifta WR) is approved “for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.” The label adds that it is “not indicated for weight loss management.”
• Bremelanotide (Vyleesi) is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

A prescriber may use an approved drug off-label. FDA says healthcare providers “generally may prescribe the drug for an unapproved use” when they judge it medically appropriate, but that FDA “has not determined that the drug is safe and effective for the unapproved use.” That is a real distinction worth asking about.

Compounded drugs are a separate category. FDA’s wording is that “compounded drugs are not FDA-approved,” and that it “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.” A compounded peptide is legal when a state-licensed pharmacy makes it for a named patient from a substance it is allowed to use, or when an FDA-registered outsourcing facility makes it under manufacturing rules.

What changed for clinics in October 2026?

Six of the peptides that make clinic programs distinctive now sit in a new and narrow position. BPC-157, TB-500, KPV, MOTS-c, epitalon and semax were recommended for the compounding list by an FDA advisory committee in July 2026, against FDA staff advice. On October 30, 2026 HHS, through the Secretary’s office rather than FDA, published an interim policy on them. As of November 2, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding one of the six when ten conditions are met, until a final rule decides each one.

The limits decide what this means in a real clinic:

• None of the six is FDA-approved. None is on the 503A bulks list, and no rule has been proposed. HHS’s notice calls the policy a draft in places, says it “does not establish any rights for any person,” and takes comments until November 13, 2026.
• Form and route are fixed. Injected KPV and injected semax are not covered, for example. The tracker has the full table.
• Blends are out. The policy requires a single active ingredient, so products such as the Wolverine stack fall outside it even when every ingredient is on the list.
• Outsourcing facilities are out. The policy covers 503A compounding only.
• Oral products need extra proof. The compounder has to keep documentation that the formulation reaches adequate oral bioavailability in humans.
• States can be stricter. State boards of pharmacy license these pharmacies and keep their own rules, and states may not follow the federal approach.
• The evidence has not moved. This is a decision about enforcement. It says nothing about whether a peptide works or is safe.

CJC-1295, ipamorelin, AOD-9604 and selank are not in the policy, so a program built on them gets no cover from it.

How to evaluate a peptide clinic

The questions below separate a medical service from a storefront. None of them is about price or results; they are about whether the product and the prescription are real.

1. Is there a licensed prescriber who actually evaluates you?

A prescription needs a prescriber licensed in your state, usually a physician, nurse practitioner or physician assistant. State licensing boards publish license lookups by name. A real evaluation covers your history, other medicines and conditions that rule a drug out, such as the thyroid cancer history that bars GLP-1 drugs. A checkout page that picks a peptide and a dose for you is not an evaluation. In September 2026, FDA questioned a compounder whose prescriptions were generated through preselected options on telehealth platforms.

2. Who dispenses it?

The drug should come from one of these places, and the label should say which:

A state-licensed pharmacy can be checked on the state board of pharmacy’s website. A 503B facility can be checked on FDA’s registered outsourcing facilities list, which FDA says is generally updated weekly. FDA notes that registration means only that the facility submitted the required information, not that it passed inspection.

3. Is anything labeled “research use only”?

If a clinic hands over, ships or tells you to order a vial marked “research use only” or “not for human consumption,” it is not a pharmacy product and not legal for human use. Federal rules allow such products to be shipped only for laboratory or animal research. FDA warning letters to peptide sellers, including five sent on August 24, 2026, found that a research label does not change what a product is when the seller supplies dosing guidance and reconstitution calculators. The HHS policy gives these products nothing, and says its purpose includes discouraging their use.

4. Does the product match what the policy describes?

If a clinic offers one of the six peptides and points to the HHS policy, the details can be checked against it. The label should read “This is a compounded drug product. Not for resale.” The product should contain one active ingredient, in a form and route the policy lists, made for you on a patient-specific prescription. The only device packaged with it should be an FDA-cleared syringe, and the guide to reading a COA explains the testing behind the ingredient. Meeting these conditions does not make the product approved. Missing them means the policy does not apply at all.

5. Does the marketing describe the products honestly?

FDA sent 30 warning letters to telehealth companies on March 3, 2026 over compounded GLP-1 marketing. The claims it objected to included calling a compounded product “FDA-approved,” describing it as “generic Zepbound,” and wording that implied the product was the approved drug. Any program that calls a compounded or unapproved peptide “FDA approved” is misdescribing it, and that includes presenting the HHS policy as an approval.

6. Do they say what the evidence is?

For an approved drug, the answer is the label and its trials. For most other clinic peptides, the honest answer is animal studies or small early human studies. FDA’s own review of BPC-157 said the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans.” A clinic that describes these peptides as proven is overstating the evidence. Each peptide profile on this site states the evidence level up front.

Red flags

• No prescriber evaluation, or a prescriber you cannot identify by name and license.
• Vials with no patient name, no pharmacy name, or a research-use label.
• A drug called “FDA approved” when it is compounded or unapproved.
• A blend of several peptides presented as covered by the HHS policy.
• Semaglutide sodium or semaglutide acetate on the label. FDA says these salt forms are different active ingredients from the approved drugs and it knows of no lawful basis for compounding with them.
• Retatrutide or cagrilintide offered as a compounded product. FDA says they “cannot be used in compounding under federal law.”
• Instructions to mix a powder with water you are told to source yourself. A pharmacy-dispensed powder comes with the diluent or names the one to use; the reconstitution guide explains why that matters.

What does peptide therapy cost, and does insurance cover it?

Clinic peptide programs rarely publish prices in a form that can be checked and dated, so PeptideSorted does not print them. For the approved drugs, prices are public: the tirzepatide cost page and cheapest GLP-1 without insurance list dated prices with their sources.

Insurance does not cover a program as such. Plans decide coverage drug by drug and diagnosis by diagnosis, so the useful question to your plan names the specific drug and the reason for it. Ask before paying a clinic, and ask the clinic for an itemized breakdown of what the fee includes.

What to watch for

The drug risks are the same whoever prescribes them: the label’s warnings apply to an approved drug in a clinic exactly as they do at a hospital. What a clinic setting adds is the risk of the product. Compounded GLP-1s have generated more than 1,700 FDA adverse event reports, some tied to dosing errors with vials and syringes, and unapproved peptides have no human safety data at all. The are peptides safe guide sets out what is known for each kind.